Competitive Transfer of αCD19-TCRz-CD28 and αCD19-TCRz-CD137 CAR-T Cells for B-cell Leukemia/Lymphoma
Status:
Unknown status
Trial end date:
2019-12-01
Target enrollment:
Participant gender:
Summary
This is a single-arm open-label phase I/II study to determine the relative superiority of
αCD19-TCRζ-CD28 and αCD19-TCRζ-CD137 CAR-T Cells in safety, efficacy and engraftment
potential in patients with CD19+ B-lineage leukemia and lymphoma. Recently, cancer
immunotherapy, treatments aiming to arm patients with immunity specifically against cancer
cells, has emerged as a promising therapeutic strategy. Clinical trials utilizing CARs
against B cell malignancies have demonstrated remarkable potential. In this trial, all
subjects will be competitively infused with αCD19-TCRz-CD28 and αCD19-TCRz-CD137 CAR-T cells
in equal number to test a hypothesis that CD137-costimulation can promote the persistence and
engraftment of CAR-T cells and this superiority can lead to improved progression-free
survival.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
The Second Affiliated Hospital of Henan University of Traditional Chinese Medicine
Collaborators:
Xinqiao Hospital of Chongqing Xuzhou Medical University